Add a Comment

In response to:

In the beginning of this year, I wrote two articles concerning torcetrapib, the $800 million failure of Pfizer to develop a new type of cholesterol medication. This novel medication called a CETP (cholesterol ester transfer protein) inhibitor i...

Subject:

Comment:

I am a registered user

Name:		Note: Username is not required. Please remember that this Username will be publicly visible on this site and the rest of the Internet.
Email:		Your email helps us get in touch if necessary. Your e-mail address will not be posted on our site and will be kept confidential as provided in our Privacy Policy.

Type the letters shown in the box to the right:

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Non-Profit Affiliates:

Featuring Content From:

By using this service, you accept our Terms of Use. Please read them. The consumer health information on CholesterolNetwork.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2008. The HealthCentral Network, Inc. All rights reserved.

We comply with the HONcode standard for trustworthy health information: verify here.


Email:
Password:
Remember Me:

Sign in

CholesterolNetwork.com

Add a Comment